Sovereign Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SOVEREIGN PHARMS, and when can generic versions of SOVEREIGN PHARMS drugs launch?
SOVEREIGN PHARMS has two approved drugs.
There are three US patents protecting SOVEREIGN PHARMS drugs.
Drugs and US Patents for Sovereign Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sovereign Pharms | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 204900-003 | Jul 23, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Sovereign Pharms | OBREDON | guaifenesin; hydrocodone bitartrate | SOLUTION;ORAL | 205474-001 | Nov 14, 2014 | DISCN | Yes | No | 9,808,431 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Sovereign Pharms | OBREDON | guaifenesin; hydrocodone bitartrate | SOLUTION;ORAL | 205474-001 | Nov 14, 2014 | DISCN | Yes | No | 10,105,324 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Sovereign Pharms | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 204900-001 | Jul 23, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Sovereign Pharms | OBREDON | guaifenesin; hydrocodone bitartrate | SOLUTION;ORAL | 205474-001 | Nov 14, 2014 | DISCN | Yes | No | 9,549,907 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
Sovereign Pharms | AMLODIPINE BESYLATE | amlodipine besylate | TABLET;ORAL | 204900-002 | Jul 23, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.